INTRODUCTION

Hidradenitis suppurativa (HS) is a chronic inflammatory disease that affects all aspects of a patient’s life. The estimated prevalence of HS varies from 0.05% to 4.10%.1,2 Patients usually present with painful and inflamed nodules, abscesses, and pus-discharging sinus tracts, which typically occur in apocrine-gland-bearing areas like the armpits, groin, and gluteal and perianal regions. The frequent pus discharge and unpleasant odor have a significant negative effect on the patient’s well-being.3

Despite the availability of multiple medical treatment modalities, severe cases have little or no response, making surgery the mainstay of treatment.4,9,10 Surgical management of HS is complex and requires a multidisciplinary approach.11,12 Refractory cases require surgical excision and wide debridement of the involved tissues. The options of reconstruction after excision follow the reconstructive surgery ladder, which includes healing by secondary intention, split thickness skin grafting, or flap coverage.

In this article, we describe our experience in treating HS of the axilla with excision and simultaneous locoregional lateral chest flap coverage. We aimed to shine the light on the advantages of using this reconstructive method when compared with other options mentioned in the literature.

METHODS

We included 14 patients who presented to our clinic from January 2017 to May 2021 with the complaint of severe bilateral axillary hidradenitis (Hurley stage III) for a mean period of 7 years. Our patients tried different treatment modalities for extended periods of time but showed a poor response; therefore, they were referred to us by their dermatologists. At the time of definite surgery, there was no acute infection (abscess, cellulitis, etc) in any of the cases. The method of treatment used was extensive debridement and excision of axillary glands corresponding to the borders of axilla bilaterally, with immediate reconstruction using lateral chest flaps. They received a full course of antibiotics for 7 days starting from the day of surgery. They were discharged home when drain output...
was less than 10 mL. Most of the patients are still following our clinic except for those who left the country. The mean follow-up period was 1 year.

Six months after the procedure, the aesthetic outcome was measured through asking the patients how they rate the appearance of their scars (unsatisfactory—satisfactory—good), and the functional outcome was measured through assessing the shoulders’ range of motion (restricted range of motion versus full range of motion).

SURGICAL TECHNIQUE
Complete excision of the affected axillary skin and subcutaneous tissue to the level of the axillary fascia was performed. Marking of the transpositional lateral chest flap was then performed. The designed flap should lie between the anterior and posterior axillary lines and should not cross the subcostal margin inferiorly. The flap size was chosen slightly bigger than the defect with the biggest flap measuring 20 × 10 cm. Dissection was performed in a subfascial plane starting from the distal tip using bipolar diathermy and tenotomy scissors. The dissection was continued to a point where we were able to mobilize the flap to cover the defect, bearing in mind that most of the perforators that supply this flap traverse the fascia at the level of the third intercostal space. In the cases where we needed to go above this level, the thoracodorsal artery perforators were the main supply to the flap; below this level more perforators contribute to the vascular supply of the flap. We used the Doppler to identify and mark the thoracodorsal artery perforator that emerges 2 cm posterior to the posterior axillary line at its superior end, and to know our limitation of proximal dissection in case we needed more mobility of the flap. However we did not have to reach that level in any of our cases. The flap was fixed to the defect using 2-0 Vicryl subcutaneous interrupted stitches and simple interrupted suturing of the skin. The donor area was closed primarily in two layers in all cases, and a drain was placed on each side (Fig. 1).

RESULTS
The patients were all men with a mean age of 33.7 years. Mean operative time was 45 minutes for each side. Thirteen patients had complete healing of the donor and recipient sites without any further intervention, and one patient required re-suturing because of significant wound gapping. Flap necrosis, contractures, and lymphedema did not occur with any patient. A total of four patients who are smokers had wound gapping, three of them did not require any intervention and had complete healing within three weeks, and one patient needed resuturing, as he suffered from hematoma due to immature removal of the drain.

No wound infection was encountered with any case. Mean in-hospital stay was three days, and patients were able to return to work after 2 weeks.

At six months postoperatively, all patients had rated their cosmetic results as good, and all of them had full range of motion of the shoulder joints without contractures (Fig. 2). The only noted complaint was bulkiness at the base of the flap in one patient, which was treated with liposuction to flatten the area with satisfactory results. Our mean follow-up period for the patients was 1 year, and no recurrences were noted (Table 1).

DISCUSSION
Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the apocrine sweat glands, which usually get activated around the age of puberty. It is classified into mild, moderate, and severe according to the Hurley clinical staging system. Stage III is the most severe form of the disease, which is described as combined lesions with tunnel formation, scarring, and inflammation.

HS is mainly diagnosed through clinical examination based on the nature and site of the lesions, in addition to the disease course. The treatment objectives are to manage the existing lesions, prevent new lesions, and minimize the psychological morbidity that is associated with the disease. Treatment options vary from pharmacological to surgical, in addition to lifestyle modifications. The selected option should be tailored according to the disease severity and the patient’s condition.

Pharmacological options depend on the severity of the disease. In mild or moderate cases, a long course of antibiotics can be sufficient. In severe and antibiotic-resistant cases, anti-inflammatory or immunosuppressive therapy can be used with many associated drawbacks, such as marked side effects, long treatment course, and high rates of relapse after the end of the course.

The surgical option comes into play in the most severe and resistant cases for which the pharmacological treatment fails to provide any improvement. Current surgical procedures for treating HS include cryo-insufflation, incision, and drainage, deroofing, skin-tissue–saving excision with electrosurgical peeling, and wide surgical excision.

Wide surgical excision includes removal of the visible lesions plus an area of surrounding disease-free tissue. It has the advantage of lower recurrence rate compared with other techniques. The defect that results from this excision can either be reconstructed or left for secondary intention healing, which has a long postoperative recovery time. Primary closure is not an option when performing wide surgical excision; however, it still has a role in limited disease.

A split thickness skin graft (STSG) can be used to cover the defect after excision; it has the advantage of

Takeaways

Question: What is the optimal treatment of severe axillary hidradenitis?

Findings: No recurrence for the studied time with good cosmetic and functional results.

Meaning: Wide excision and immediate reconstruction with locoregional (lateral chest) flap is a reliable option.
less recovery time and low recurrence rate compared with secondary intention healing. Its disadvantages include the prolonged period of immobilization required postoperatively, which may result in contractures—the less cosmetically appealing outcome when compared with locoregional flaps (which replace the defect with similar tissue), and the added donor-site morbidity such as delayed healing and insightful scarring. Some authors attempted applying negative pressure therapy over the graft to increase the intake and others advocated the use of a bilayer dermal regeneration template to improve cosmetic outcomes. In a case study, Pearce et al used STSG to reconstruct the defects post excision for seven patients with HS. They reported no failure with acceptable functional and cosmetic outcomes. However, the mean in-hospital stay was 10 days with more than one operation, and they were inclined to apply negative pressure dressing for a couple of days. Comparing this with our method of immediate reconstruction with a locoregional lateral chest flap, we achieved a significant decrease in the in-hospital stay.

Flaps are the optimum reconstructive option because they replace the defect with look-alike tissue with good padding and excellent cosmetic results. Functionally, they are better than skin grafts because they require less recovery and immobilization time, which in turn leads to less contracture incidence. Fasciocutaneous V-Y flaps, Limberg flaps, musculocutaneous flaps, and perforator flaps like the thoracodorsal artery perforator flap and circumflex scapular artery perforator flap have been used for the reconstruction of the axilla after excision of HS.

Afhsarfard et al compared the use of STSG with random parascapular flap in reconstruction post resection. Their report showed no difference in terms of pain, patient satisfaction, or range of motion. In contrast to our way of immediate reconstruction, they delayed the reconstruction for 2–3 weeks post resection to obtain good granulation tissue in their method.

The lateral chest (thoracic region) flap was described by Bhattacharya et al in 1990 as a choice of regional reconstruction. The flap is supplied by multiple perforators that traverse the deep fascia at the level of the third intercostal space. In our series, we used this flap for immediate reconstruction of the defect caused by the resection of the affected areas. The advantages of using this flap include its reliability because of the abundant blood supply, its ease of dissection, a one-stage surgery, replacing like-to-like tissues, and the ability to perform primary closure of the donor site.

The thoracodorsal artery perforator (TDAP) flap is a modified form of the lateral chest flap where the flap is raised on a specific vascular pedicle. It is a relatively new option in reconstructive surgery. It has been used as a pedicled flap for the reconstruction of regional soft tissue defects, including the trunk, axilla, and breast. It has also been used as a free flap in reconstruction of distant tissue defects such as the face, elbow, forearm, and lower extremity. Advantages of the TDAP flap include simultaneous flap elevation, relative ease of dissection, minimal donor-site morbidity, and constant vascular anatomy with a long pedicle. It is described for the reconstruction after wide excision of axillary hidradenitis in different forms (Island, Propeller, V-Y) with encouraging results.

Wormald et al compared the use of TDAP versus a skin graft after wide local excision of severe axillary hidradenitis. According to their results, TDAP was superior to the use of skin graft in terms of improving recovery time, fewer postoperative complications, shorter follow-up periods, and...
better postoperative quality of life. Busnardo et al focused on the functionality gains after axillary reconstruction with TDAP during their study. They observed a mean increase of 54 degrees in arm abduction in their treated patients.

Our approach in treating axillary hidradenitis corresponds to the recommendations in the literature. Wide excision with 1–2 cm safe margins is key to remove all the diseased hair follicles and apocrine glands. In our cases, we extended the excision more to include the whole axillary region to help reduce the rate of recurrence and need for further excisions. It is worth mentioning that there was no acute infection (abscess, cellulitis, etc.) in any of the cases; if this was the case, then the patient should be treated with a course of antibiotics till the infection subsides, to minimize the risk of postoperative surgical site infection. Patients were left with big raw areas; our mean defect size was around 10 × 8.6 cm. We opted to reconstruct the raw areas in the same surgery to minimize hospital stay and fasten recovery time, which helps avoid future contractures and gives a cosmetic advantage.

We used the lateral chest flap described earlier as a reliable way of reconstruction. Care must be taken not to cross the subcostal margin inferiorly to avoid distal necrosis and associated complications. Using this method, the defect was covered with look-alike tissue. The ease of dissection without the need to isolate a pedicle makes it an easy and safe option to use, even for surgeons who are not familiar with the concept of perforator flaps. It also decreases the operative time. Our patients stayed in the hospital for 3 days on average and were able to get back to work in 2 weeks. They received prophylactic antibiotic on the day of surgery, and for 1 week after the operation, dressing was changed daily by the patients at home until full healing of the wound was judged on the clinical visit. We had four incidents of wound dehiscence, which were all encountered in smokers and required no further surgical intervention, except for one case that needed re-suturing. Our recurrence rate at a mean follow-up time of 12 months was zero. Bulkiness at the base of the flap was the only concern faced in one patient, and it was managed by
liposuction in a second-stage surgery, which was done one-and-a-half years after the procedure.

In conclusion, this study aimed to introduce and encourage a treatment option for axillary hidradenitis of grade II and III based on the Hurley classification, which includes an extended axillary excision deep to the fascial level, ensuring complete excision of the affected area, with immediate reconstruction using the lateral chest flap as a reliable, easy, and fast way of reconstruction without an increased risk of infection or flap loss.

The limitation of this study is the low number of patients and the short period of follow-up to determine the actual recurrence rate. We recommend testing this theory on a larger number of patients for an extended period of follow-up time and using stronger study designs to compare this method with other ways of reconstruction.

**REFERENCES**

1. Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. *J Am Acad Dermatol*. 2015;73(5 Suppl 1):S4–S7.

2. Ingram JR, Jenkins-Jones S, Knipe DW, et al. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. 2018;178:917-924.

3. Saunte DML, Jemec GBE. Hidradenitis suppurativa: advances in diagnosis and treatment. *JAMA*. 2017;318:2019-2032.

4. Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. *J Eur Acad Dermatol Venereol*. 2015;29:619-644.

5. Join-Lambert O, Coignon H, Jais JP, et al. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. *Dermatology*. 2011;222:49-58.

6. Boer J, van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. *J Am Acad Dermatol*. 1999;40:73–76.

7. Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. *N Engl J Med*. 2016;375:422-434.

8. Miller I, Lynghaar CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. *Br J Dermatol*. 2011;165:391–398.

9. Posch C, Monshi B, Quint T, et al. The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): Retrospective analysis of 74 patients. *J Am Acad Dermatol*. 2017;77:123–129.e5.

10. Danby FW, Hazen PG, Boer J. New and traditional surgical approaches to hidradenitis suppurativa. *J Am Acad Dermatol*. 2015;73(5 Suppl 1):S62–S65.

11. Ruan QZ, Chen AD, Singhal D, et al. Surgical management of hidradenitis suppurativa: procedural trends and risk factors. *J Surg Res*. 2018;229:200–207.

12. Gulliver W, Zouboulis CC, Prens E, et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. *Rev Endocr Metab Disord*. 2016;17:343–55.
13. Morgan WP, Harding KG, Hughes LE. A comparison of skin grafting and healing by granulation, following axillary excision for hidradenitis suppurativa. *Ann R Coll Surg Engl*. 1983;65:235–236.

14. Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: an update. *J Am Acad Dermatol*. 2015;73(5 Suppl 1):S8–11.

15. Al Lahham S MD, Aljassem G MD, Al-Bassi H MD, Alyazji Z T.N. MD, Sada R MD. Grafting a spherical hidradenitis-affected scrotal raw area using a sterile glove: a case report describing the Al Lahham technique. *IJS: Short Reports*: 2020;5:e11

16. Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: *Dermatologic Surgery*, Roenigk RK, Roenigk HH (Eds), New York: Dekker; 1989:729.

17. Sabat R, Jemec GBE, Matusiak Ł, et al. Hidradenitis suppurativa. *Nat Rev Dis Primers*. 2020;6:18.

18. Freysz M, Jemec GB, Lipsker D. A systematic review of terms used to describe hidradenitis suppurativa. *Br J Dermatol*. 2015;173:1298–1300.

19. Vellaichamy G, Braunberger TL, Nahhas AF, et al. Surgical procedures for hidradenitis suppurativa. *Caitis*. 2018;102:13–16.

20. Ellis LZ. Hidradenitis suppurativa: surgical and other management techniques. *Dermatol Surg*. 2012;38:517–536.

21. Mehdizadeh A, Hazen PG, Bechara FG, et al. Recurrence of hidradenitis suppurativa after surgical management: a systematic review and met-analysis. *J Am Acad Dermatol*. 2015;73(5 Suppl 1):S70–S77.

22. Nail-Barthelemy R, Stroumza N, Qassemyar Q, et al. Evaluation of the mobility of the shoulder and quality of life after perforator flaps for recalcitrant axillary hidradenitis [published online February 13, 2018]. *Ann Chir Plast Esthet*. 2019;64:68–77.

23. Sever C, Uygur F, Kulahci Y, et al. Thoracodorsal artery perforator fasciocutaneous flap: A versatile alternative for coverage of various soft tissue defects. *Indian J Plast Surg*. 2012;45:478–484.

24. Taylor EM, Hamaguchi R, Kramer KM, et al. Plastic surgical management of hidradenitis suppurativa. *Plast Reconstr Surg*. 2021;147:479–491.

25. Wormald JC, Balzano A, Clibbon JJ, et al. Surgical treatment of severe hidradenitis suppurativa of the axilla: thoracodorsal artery perforator (TDAP) flap versus split skin graft. *J Plast Reconstr Aesthet Surg*. 2014;67:1118–1124.

26. Dabernig J, Sorensen K, Shaw-Dunn J, et al. The thin circumflex scapular artery perforator flap. *J Plast Reconstr Aesthet Surg*. 2007;60:1082–1096.

27. Pearce FB Jr, Richardson KA. Negative pressure wound therapy, staged excision and definitive closure with split-thickness skin graft for axillary hidradenitis suppurativa: a retrospective study. *J Wound Care*. 2017;26(Supp1):S30–S42.

28. Afsharfar A, Khodaparast MB, Zarrintan S, et al. Comparison of split thickness skin grafts and flaps in bilateral chronic axillary hidradenitis suppurativa. *World J Plast Surg*. 2020;9:55–61.

29. Busnardo FF, Coltro PS, Olivan MV, et al. The thoracodorsal artery perforator flap in the treatment of axillary hidradenitis suppurativa: effect on preservation of arm abduction. *Plast Reconstr Surg*. 2011;128:949–953.

30. Gonzaga TA, Endorf FW, Mohr WJ, et al. Novel surgical approach for axillary hidradenitis suppurativa using a bilayer dermal regeneration template: a retrospective case study. *J Burn Care Res*. 2013;34:51–57.

31. Bhattacharya S, Bhagia SP, Bhatnagar SK, et al. The lateral thoracic region flap. *Br J Plast Surg*. 1990;43:162–168.